Our client, Duke-NUS, has helped to develop a new, rapid serological test for determining whether someone has had COVID-19.
The test, known as the cPass™, was launched in collaboration with global biotechnology company GenScript and Singapore’s Agency for Science, Technology and Research (A*STAR).
When a person is infected with SARS-CoV-2, their immune response produces antibodies to the virus, some of which are neutralising antibodies (NAbs) capable of blocking binding of the virus to host cells. The cPass™ is the first test in the world capable of rapidly detecting the presence of NAbs in the blood or serum.
Unlike many existing COVID-19 lab-based antibody tests, the cPass™ does not involve the use of live virus or cells, and therefore does not require processing by highly-skilled operators in biocontainment facilities.
As countries begin to formulate strategy for exit from lockdown, the cPass™ is set to help with our understanding of infection rates and evaluation of humoral protection against the virus.
Read more about these developments: The Straits Times, PR Newswire.
